The novel coronavirus pandemic has upended our lives, creating a far-from-normal “new normal.” And it has also given rise to countless collaborations between and among universities, hospitals, medical centers, pharma companies and others to pool their talent and resources to discover, test, manufacture and distribute diagnostics, treatments, vaccines, personal protective equipment and other resources needed to fight the pandemic. Antitrust law poses no risk to these collaborations, so long as they remain focused on their core missions. But at the same time, antitrust law recognizes that in cooperating and exchanging information and insights for those missions there is the potential for “spill-over effects” that can create antitrust risk. The trick is to know where that dividing line is and to avoid crossing over it.
- (Not) Copyright Infringement: Is dbrand Infringing Nintendo’s IP?
- The Transmissibility of Information: How Your Trade Secrets Are Like a Virus
- Examining Antitrust Guidance on Cooperation in Fighting COVID-19
- Everything Depends on Coronavirus R&D Partnerships—Don’t Let the Critics Wreck Them
- Boys Will Be Boys: Getting a Foot in the Funding Door for Women Entrepreneurs
- Defensive Publications: A Cost-Effective Tool to Supplement Your Patent Strategy
- A Stylized Word Mark in One Country May Be Too Simple and Common in Another
- Other Barks & Bites for Friday, May 22: Copyright Office Issues Section 512 Safe Harbor Report, CAFC Denies Review of PTAB Institution Decision and Director Iancu on Possible Filing Deadline Extension
- CAFC Finds Claim for Delivery Notification System Abstract as Directed to a Longstanding Commercial Practice
- PTAB Institution Data Analysis Proves That Reforms Have Failed